First Allied Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

First Allied Advisory Services’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.08M	Sell	1,939 -1,261	-39%	-$765K	0.04%	451
2020 Q2	$2M	Buy	3,200 +1,259	+65%	+$715K	0.07%	271
2020 Q1	$948K	Sell	1,941 -66	-3%	-$27.2K	0.04%	402
2019 Q4	$758K	Sell	2,007 -1,082	-35%	-$364K	0.03%	573
2019 Q3	$853K	Sell	3,089 -555	-15%	-$164K	0.03%	509
2019 Q2	$1.14M	Sell	3,644 -5	-0.1%	-$1.67K	0.04%	427
2019 Q1	$1.49M	Buy	3,649 +74	+2%	+$30.5K	0.05%	357
2018 Q4	$1.33M	Buy	3,575 +501	+16%	+$183K	0.05%	350
2018 Q3	$1.24M	Buy	3,074 +424	+16%	+$161K	0.04%	411
2018 Q2	$913K	Buy	2,650 +415	+19%	+$130K	0.03%	482
2018 Q1	$767K	Buy	2,235 +27	+1%	+$9.39K	0.03%	528
2017 Q4	$835K	Buy	2,208 +354	+19%	+$143K	0.03%	497
2017 Q3	$827K	Buy	1,854 +226	+14%	+$108K	0.04%	467
2017 Q2	$797K	Sell	1,628 -40	-2%	-$17.5K	0.04%	483
2017 Q1	$646K	Buy	1,668 +53	+3%	+$19.6K	0.03%	503
2016 Q4	$593K	Buy	1,615 +119	+8%	+$45.3K	0.03%	530
2016 Q3	$601K	Buy	1,496 +90	+6%	+$36.1K	0.03%	506
2016 Q2	$487K	Buy	1,406 +60	+4%	+$23.1K	0.03%	560
2016 Q1	$485K	Sell	1,346 -815	-38%	-$336K	0.03%	548
2015 Q4	$1.17M	Buy	2,161 +89	+4%	+$48.2K	0.06%	328
2015 Q3	$962K	Sell	2,072 -71	-3%	-$38.1K	0.05%	357
2015 Q2	$1.1M	Sell	2,143 -158	-7%	-$77.1K	0.05%	373
2015 Q1	$1.03M	Sell	2,301 -180	-7%	-$76.3K	0.07%	343
2014 Q4	$1.01M	Sell	2,481 -1,236	-33%	-$486K	0.07%	317
2014 Q3	$1.34M	Buy	3,717 +720	+24%	+$241K	0.11%	227
2014 Q2	$846K	Sell	2,997 -257	-8%	-$76.2K	0.06%	368
2014 Q1	$977K	Buy	3,254 +2,304	+243%	+$710K	0.07%	305
2013 Q4	$261K	Sell	950 -1,838	-66%	-$529K	0.02%	726
2013 Q3	$871K	Buy	+2,788	New	+$733K	0.05%	344

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Allied Advisory Services's REGN Position: Q3 2020 in Review

First Allied Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 39% in Q3 2020, selling an estimated $765K and leaving 1,939 shares worth $1.08M. The position accounts for 0.04% of the portfolio, ranked #451.

First Allied Advisory Services first reported a position in REGN in Q3 2013 and has held it in 29 quarters since. The position peaked at $2M in Q2 2020. 907 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

First Allied Advisory Services held 1,939 shares of Regeneron Pharmaceuticals worth $1.08M as of Q3 2020.
First Allied Advisory Services sold 1,261 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $765K.
Regeneron Pharmaceuticals made up 0.04% of First Allied Advisory Services's portfolio in Q3 2020, its #451 holding.
First Allied Advisory Services first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 29 quarters since.
First Allied Advisory Services's Regeneron Pharmaceuticals position peaked at $2M in Q2 2020.
907 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.